ALNY FY 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$220M+193.4% YoY

Gross Profit

$195M88.6% margin

Operating Income

-$939M-427.5% margin

Net Income

-$886M-403.2% margin

EPS (Diluted)

$-8.11

Cash Flow

Operating Cash Flow

-$278M

Free Cash Flow

-$419M

Stock-Based Comp.

$175M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$956M

Stockholders' Equity

$1.4B

Cash & Equivalents

$547M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220M	$75M	+193.4%
Gross Profit	$195M	$73M	+166.3%
Operating Income	-$939M	-$815M	-15.3%
Net Income	-$886M	-$761M	-16.4%